BioNTech închide trei fabrici din Germania

BioNTech plans to close three production sites in Germany by 2028, affecting around 1,800 employees, due to market conditions and a shift in focus towards cancer treatments. The closures are part of a broader restructuring aimed at consolidating production capabilities amid reduced demand for COVID-19 vaccines. The company reported a significant drop in revenue and a net loss in the first half of 2026, prompting this strategic change. BioNTech aims to develop a diverse biopharmaceutical portfolio with oncology at its core by 2030, expecting annual savings of approximately 500 million euros from these efficiency measures.